



BMS-564929

Catalog No: tcsc1381

Available Sizes	
Size: 5mg	
Size: 10mg	
Size: 50mg	
Specifications	
CAS No: 627530-84-1	
Formula: C ₁₄ H ₁₂ CIN ₃ O ₃	
Pathway: Others	
Target: Androgen Receptor	
Purity / Grade: >98%	
Solubility: 10 mM in DMSO	
Observed Molecular Weight:	

Product Description

305.72

BMS-564929 is an **androgen receptor** (AR) agonist, binds to androgen receptor (AR) with a $\mathbf{K_i}$





of 2.11±0.16 nM.

IC50 & Target: Ki: 2.11±0.16 nM (Androgen receptor)[1]

In Vitro: BMS-564929 exhibits a potency (EC $_{50}$, calculated as the concentration at which 50% of the maximum stimulatory effect of DHT is achieved) of 0.44±0.03 nM in the C2C12 myoblast cell line. In the PEC cell line, the EC $_{50}$ for BMS-564929 is 8.66±0.22 nM. BMS-564929 is more than 1000-fold selective for AR vs. estrogen receptors (ER) α and β , glucocorticoid receptor (GR), and mineralocorticoid receptor (MR), and approximately 400-fold selective vs. progesterone receptor (PR). BMS-564929 shows no measurable activity in functional transactivation assays with ER α/β , GR, MR, or PR at concentrations up to 30 μ M^[1].

In Vivo: In sexually mature, castrated male rats, a well-characterized animal model, BMS-564929 (p.o.) shows substantially more potent activity in the levator ani, exhibiting an ED_{50} of 0.0009 mg/kg in the levator ani and an ED_{50} of 0.14 mg/kg in the prostate; a net 160-fold selectivity for muscle vs. prostate. Approximately 100% muscle stimulation is achieved at 0.1 mg/kg, reaching greater than 125% stimulation at 0.3 and 1 mg/kg. Compared with T propionate (TP) in the same model, BMS-564929 is more than 200 times more potent in stimulation of muscle and 80 times more selective for muscle vs. prostate^[1].

$$\begin{array}{c|c}
 & O \\
 & N \\
 & N \\
 & H \\
 & O \\
 & CI
\end{array}$$

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!